Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

In children with moderate-to-severe asthma, telemedicine intervention with therapy in schools improves asthma outcomes, ...

Please provide your email address to receive an email when new articles are posted on . Patients with mild asthma are still at risk for severe exacerbations, which can impact their quality of life.

Blood eosinophil count and fractional exhaled nitric oxide (FeNO) play an important role in selecting biological therapies for severe asthma. This analysis of patient-level data pooled across 22 ...

Down-titrating vial concentrations when restarting subcutaneous allergen immunotherapy after treatment gaps may help lower ...

This week, Dr Ray O’Connor takes a look at recent clinical articles on the management of asthma, and what environmental ...

For decades, scientists believed molecules called leukotrienes were the main culprits behind asthma’s airway-constricting ...

AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation ...

Posters presented at ACAAI 2023 Annual Scientific Congress examined dupilumab use in children with moderate-to-severe asthma and in the presence of elevated type 2 biomarkers. Two posters presented at ...

For decades, scientists have thought they understood the biochemical machinery that causes asthma—inflammation in the lungs that constricts airways and makes it hard to breathe.

Mepolizumab significantly reduced healthcare resource utilization, including hospitalizations and emergency department visits, in patients with severe eosinophilic asthma over two years. The treatment ...